Diffuse Large B Cell Lymphoma Clinical Trials in New York, New York
16 recruitingNew York, New York
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 1Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled70 locationsNCT06395103
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Early Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell LymphomaB-ALLDLBCL Unclassifiable+7 more
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT04512716
Recruiting
Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+4 more
SWOG Cancer Research Network396 enrolled87 locationsNCT05633615
Recruiting
Not Applicable
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+2 more
Hua-Jay J Cherng, MD40 enrolled1 locationNCT06693830
Recruiting
Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma
AbbVie154 enrolled20 locationsNCT05512390
Recruiting
Phase 2
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaStage III High Grade B-Cell Lymphoma+7 more
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT06736613
Recruiting
Not Applicable
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoma, B-Cell+3 more
Memorial Sloan Kettering Cancer Center48 enrolled2 locationsNCT05940272
Recruiting
Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma
Karyopharm Therapeutics Inc244 enrolled176 locationsNCT02227251
Recruiting
Phase 1
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+1 more
Weill Medical College of Cornell University15 enrolled1 locationNCT05934838
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+5 more
Miltenyi Biomedicine GmbH248 enrolled25 locationsNCT04792489
Recruiting
Phase 1
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaLymphoma, Non-HodgkinFollicular Lymphoma
Weill Medical College of Cornell University38 enrolled1 locationNCT05618366